Bleeding in cardiac surgery: Its prevention and treatment - An evidence-based review

Critical Care Clinics

Volumn 21, Issue 3 SPEC. ISS., 2005, Pages 589-610

  Whitlock, Richard ^a   Crowther, Mark A ^a   Ng, Heng J ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; ARGATROBAN; BLOOD CLOTTING FACTOR; CLOPIDOGREL; DANAPAROID; DESMOPRESSIN; DIPYRIDAMOLE; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HEPARIN LYASE; HIRUDIN; HIRULOG; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT NAPC2; RECOMBINANT PROTEIN; THROMBIN; TIROFIBAN; TRANEXAMIC ACID; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

BLEEDING; BLEEDING TIME; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CLINICAL TRIAL; CRYOPRECIPITATION; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; HEART SURGERY; HUMAN; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; REVIEW; RISK FACTOR; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS;

EID: 21244443456     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2005.04.003     Document Type: Review

References (171)

1. A.J. DelRossi, A.C. Cernaianu, and S. Botros Prophylactic treatment of postperfusion bleeding using EACA Chest 96 1989 27 30
2. R.G. Johnson, R.L. Thurer, and M.S. Kruskall Comparison of two transfusion strategies after elective operations for myocardial revascularization J Thorac Cardiovasc Surg 104 1992 307 314
3. D.M. Surgenor, E.L. Wallace, and W.H. Churchill Red cell transfusions in coronary artery bypass surgery (DRGs 106 and 107) Transfusion 32 1992 458 464
4. L.J. Dacey, J.J. Munoz, and Y.R. Baribeau Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group Arch Surg 133 1998 442 447
5. J.M. Geraci, A.K. Rosen, and A.S. Ash Predicting the occurrence of adverse events after coronary artery bypass surgery Ann Intern Med 118 1993 18 24
6. K. Karkouti, D.N. Wijeysundera, and T.M. Yau The independent association of massive blood loss with mortality in cardiac surgery Transfusion 44 2004 1453 1462
7. F.D. Loop, B.W. Lytle, and D.M. Cosgrove J. Maxwell Chamberlain memorial paper. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care Ann Thorac Surg 49 1990 179 186
8. F.A. Moore, E.E. Moore, and A. Sauaia Blood transfusion: an independent risk factor for postinjury multiple organ failure Arch Surg 132 1997 620 624
9. M.J. Moulton, L.L. Creswell, and M.E. Mackey Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations J Thorac Cardiovasc Surg 111 1996 1037 1046
10. M.J. Unsworth-White, A. Herriot, and O. Valencia Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality Ann Thorac Surg 59 1995 664 667
11. J.R. Utley, E.F. Wilde, and S.A. Leyland Intraoperative blood transfusion is a major risk factor for coronary artery bypass grafting in women Ann Thorac Surg 60 1995 570 574
12. E. Moor, A. Hamsten, and M. Blomback Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion Thromb Haemost 72 1994 335 342
13. J.G. Motwani, and E.J. Topol Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention Circulation 97 1998 916 931
14. F. Bachmann, R. McKenna, and E.R. Cole The hemostatic mechanism after open-heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation J Thorac Cardiovasc Surg 70 1975 76 85
15. D.M. Cosgrove, F.D. Loop, and B.W. Lytle Determinants of blood utilization during myocardial revascularization Ann Thorac Surg 40 1985 380 384
16. L.S. Czer, T.M. Bateman, and R.J. Gray Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin J Am Coll Cardiol 9 1987 1139 1147
17. M.N. Wasser, J.G. Houbiers, and J. D'Amaro The effect of fresh versus stored blood on post-operative bleeding after coronary bypass surgery: a prospective randomized study Br J Haematol 72 1989 81 84
18. G.J. Despotis, M.S. Avidan, and C.W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann Thorac Surg 72 2001 S1821 S1831
19. G. Hartstein, and M. Janssens Treatment of excessive mediastinal bleeding after cardiopulmonary bypass Ann Thorac Surg 62 1996 1951 1954
20. R.E. Rawitscher, J.W. Jones, and T.A. McCoy A prospective study of aspirin's effect on red blood cell loss in cardiac surgery J Cardiovasc Surg (Torino) 32 1991 1 7
21. D.L. Reich, G.C. Patel, and F. Vela-Cantos Aspirin does not increase homologous blood requirements in elective coronary bypass surgery Anesth Analg 79 1994 4 8
22. P. Kallis, J.A. Tooze, and S. Talbot Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss: a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina Eur J Cardiothorac Surg 8 1994 404 409
23. S. Yende, and R.G. Wunderink Effect of clopidogrel on bleeding after coronary artery bypass surgery Crit Care Med 29 2001 2271 2275
24. D.H. Bevan Cardiac bypass haemostasis: putting blood through the mill Br J Haematol 104 1999 208 219
25. R.C. Woodman, and L.A. Harker Bleeding complications associated with cardiopulmonary bypass Blood 76 1990 1680 1697
26. T.E. Warkentin, J.C. Moore, and D.G. Morgan Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet 340 1992 35 37
27. T.E. Warkentin, J.C. Moore, and D.G. Morgan Gastrointestinal angiodysplasia and aortic stenosis N Engl J Med 347 2002 858 859
28. T.E. Warkentin, J.C. Moore, and S.S. Anand Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome Transfus Med Rev 17 2003 272 286
29. S.O. Turner-Gomes, M. Andrew, and J. Coles Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease J Thorac Cardiovasc Surg 103 1992 87 97
30. L.A. Harker, T.W. Malpass, and H.E. Branson Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release Blood 56 1980 824 834
31. E.W. Salzman Blood platelets and extracorporeal circulation Transfusion 80 1963 274 277
32. R. McKenna, F. Bachmann, and B. Whittaker The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation J Thorac Cardiovasc Surg 70 1975 298 308
33. J.D. Milam, S.F. Austin, and R.F. Martin Alteration of coagulation and selected clinical chemistry parameters in patients undergoing open heart surgery without transfusions Am J Clin Pathol 76 1981 155 162
34. P. Zilla, R. Fasol, and P. Groscurth Blood platelets in cardiopulmonary bypass operations: recovery occurs after initial stimulation, rather than continual activation J Thorac Cardiovasc Surg 97 1989 379 388
35. T.W. Malpass, S.R. Hanson, and B. Savage Prevention of acquired transient defect in platelet plug formation by infused prostacyclin Blood 57 1981 736 740
36. M. Moriau, R. Masure, and A. Hurlet Haemostasis disorders in open heart surgery with extracorporeal circulation: importance of the platelet function and the heparin neutralization Vox Sang 32 1977 41 51
37. M. Dechavanne, M. Ffrench, and J. Pages Significant reduction in the binding of a monoclonal antibody (LYP 18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation Thromb Haemost 57 1987 106 109
38. J.N. George, E.B. Pickett, and S. Saucerman Platelet surface glycoproteins: studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery J Clin Invest 78 1986 340 348
39. W. van Oeveren, L. Eijsman, and K.J. Roozendaal Platelet preservation by aprotinin during cardiopulmonary bypass Lancet 1 1988 644
40. W. van Oeveren, M.P. Harder, and K.J. Roozendaal Aprotinin protects platelets against the initial effect of cardiopulmonary bypass J Thorac Cardiovasc Surg 99 1990 788 796
41. Y.T. Wachtogel, J. Musial, and B. Jenkin Loss of platelet alpha 2-adrenergic receptors during simulated extracorporeal circulation: prevention with prostaglandin E1 J Lab Clin Med 105 1985 601 607
42. R.K. Wenger, H. Lukasiewicz, and B.S. Mikuta Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass J Thorac Cardiovasc Surg 97 1989 235 239
43. C.D. Mazer, A. Hornstein, and J. Freedman Platelet activation in warm and cold heart surgery Ann Thorac Surg 59 1995 1481 1486
44. S. Asakura, R.W. Hurley, and K. Skorstengaard Inhibition of cell adhesion by high molecular weight kininogen J Cell Biol 116 1992 465 476
45. J.I. Brody, N.J. Pickering, and G.B. Fink Concentrations of factor VIII-related antigen and factor XIII during open heart surgery Transfusion 26 1986 478 480
46. R.P. Whitlock, M. Crowther, and M.H. Blackall Warfarin cessation prior to cardiopulmonary bypass Can J Cardiol 20 Supp D 2004 63
47. C. Jern, H. Seeman-Lodding, and B. Biber An experimental multiple-organ model for the study of regional net release/uptake rates of tissue-type plasminogen activator in the intact pig Thromb Haemost 78 1997 1150 1156
48. G. Valen, E. Eriksson, and B. Risberg Fibrinolysis during cardiac surgery: release of tissue plasminogen activator in arterial and coronary sinus blood Eur J Cardiothorac Surg 8 1994 324 330
49. A.K. Chan, M. Leaker, and F.A. Burrows Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass Thromb Haemost 77 1997 270 277
50. M.A. Orchard, C.S. Goodchild, and C.R. Prentice Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets Br J Haematol 85 1993 533 541
51. L.H. Edmunds Jr, and V.P. Addonizio Jr Extracorporeal circulation R.W. Coleman J. Hirsh V.J. Marder Hemostasis and thrombosis 1987 Lippincott Philadelphia 901
52. S.F. Khuri, C.R. Valeri, and J. Loscalzo Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass Ann Thorac Surg 60 1995 1008 1014
53. N. Tabuchi, J. de Haan, and P.W. Boonstra Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass J Thorac Cardiovasc Surg 106 1993 828 833
54. N. Ellison, A.J. Ominsky, and H. Wollman Is protamine a clinically important anticoagulant? A negative answer Anesthesiology 35 1971 621 629
55. G.P. Gravlee, W.S. Haddon, and H.K. Rothberger Heparin dosing and monitoring for cardiopulmonary bypass: a comparison of techniques with measurement of subclinical plasma coagulation J Thorac Cardiovasc Surg 99 1990 518 527
56. N. Ellison, C.P. Beatty, and D.R. Blake Heparin rebound: studies in patients and volunteers J Thorac Cardiovasc Surg 67 1974 723 729
57. R. Pifarre, R. Babka, and H.J. Sullivan Management of postoperative heparin rebound following cardiopulmonary bypass J Thorac Cardiovasc Surg 81 1981 378 381
58. K.H. Teoh, E. Young, and C.A. Bradley Heparin binding proteins: contribution to heparin rebound after cardiopulmonary bypass Circulation 88 1993 II420 II425
59. O.D. Ratnoff Some therapeutic agents influencing hemostasis R.W. Coleman J. Hirsh V.J. Marder Hemostasis and thrombosis 1987 Lippincott Philadelphia 1026
60. J.C. Horrow Protamine: a review of its toxicity Anesth Analg 64 1985 348 361
61. E. Lowenstein, and W.M. Zapol Protamine reactions, explosive mediator release, and pulmonary vasoconstriction Anesthesiology 73 1990 373 375
62. A. Panos, X. Orrit, and C. Chevalley Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine Eur J Cardiothorac Surg 24 2003 325 327
63. N. Shapira, H.V. Schaff, and J.M. Piehler Cardiovascular effects of protamine sulfate in man J Thorac Cardiovasc Surg 84 1982 505 514
64. S. Karthik, A.D. Grayson, and E.E. McCarron Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay Ann Thorac Surg 78 2004 527 534
65. M. Sellman, M.A. Intonti, and T. Ivert Reoperations for bleeding after coronary artery bypass procedures during 25 years Eur J Cardiothorac Surg 11 1997 521 527
66. S. Houry, C. Georgeac, and J.M. Hay A prospective multicenter evaluation of preoperative hemostatic screening tests. The French Associations for Surgical Research Am J Surg 170 1995 19 23
67. S.I. Rapaport Preoperative hemostatic evaluation: which tests, if any? Blood 61 1983 229 231
68. C.F. Eika, O.F. Havig, and H.C. Godal The value of preoperative haemostatic screening Scand J Haematol 21 1978 349 354
69. G.F. Ramsey, D.F. Arvan, and S. Stewart Do preoperative laboratory tests predict blood transfusion needs in cardiac operations? J Thorac Cardiovasc Surg 85 1983 564 569
70. R.C. Woodman, and L.A. Harker Bleeding complications associated with cardiopulmonary bypass Blood 76 1990 1680 1697
71. B.H. Dorman, F.G. Spinale, and M.K. Bailey Identification of patients at risk for excessive blood loss during coronary artery bypass surgery: thromboelastography versus coagulation screen Anesth Analg 76 1993 694 700
72. W.F. Fassin, D.F. Himpe, and J.P. Alexander Predictive value of coagulation testing in cardiopulmonary bypass surgery Acta Anaesthesiol Belg 42 1991 191 198
73. A.B. Gelb, R.I. Roth, and J. Levin Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding Am J Clin Pathol 106 1996 87 99
74. G.P. Gravlee, S. Arora, and S.W. Lavender Predictive value of blood clotting tests in cardiac surgical patients Ann Thorac Surg 58 1994 216 221
75. G.A. Nuttall, W.C. Oliver, and M.H. Ereth Coagulation tests predict bleeding after cardiopulmonary bypass J Cardiothorac Vasc Anesth 11 1997 815 823
76. P. de Moerloose Laboratory evaluation of hemostasis before cardiac operations Ann Thorac Surg 62 1996 1921 1925
77. T.E. Warkentin, J.A. Sheppard, and P. Horsewood Impact of the patient population on the risk for heparin-induced thrombocytopenia Blood 96 2000 1703 1708
78. A.J. DelRossi, A.C. Cernaianu, and S. Botros Prophylactic treatment of postperfusion bleeding using EACA Chest 96 1989 27 30
79. J.H. Essell, T.J. Martin, and J. Salinas Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass J Cardiothorac Vasc Anesth 7 1993 410 415
80. G.J. Despotis, and L.T. Goodnough Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery Ann Thorac Surg 70 2000 S20 S32
81. S.F. Khuri, J.A. Wolfe, and M. Josa Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss J Thorac Cardiovasc Surg 104 1992 94 107
82. V.A. Ferraris, S.P. Ferraris, and A. Singh The platelet thrombin receptor and postoperative bleeding Ann Thorac Surg 65 1998 352 358
83. D.S. Holloway, L. Summaria, and J. Sandesara Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients Thromb Haemost 59 1988 62 67
84. M.J. Ray, G.A. Hawson, and S.J. Just Relationship of platelet aggregation to bleeding after cardiopulmonary bypass Ann Thorac Surg 57 1994 981 986
85. J.D. Milam, S.F. Austin, and R.F. Martin Alteration of coagulation and selected clinical chemistry parameters in patients undergoing open heart surgery without transfusions Am J Clin Pathol 76 1981 155 162
86. J.F. Hirsh, T.E. Warkentin, and R.F. Raschke Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety Chest 114 5 Suppl 1998 489S 510S
87. G.J. Despotis, and J.H. Joist Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update J Cardiothorac Vasc Anesth 13 1999 18 29
88. D.J. Murray, W.J. Brosnahan, and B. Pennell Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays J Cardiothorac Vasc Anesth 11 1997 24 28
89. L.T. Goodnough, M.F. Johnston, and P.T. Toy The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group JAMA 265 1991 86 90
90. E.P. Stover, L.C. Siegel, and R. Parks Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Institutions of the Multicenter Study of Perioperative Ischemia Research Group Anesthesiology 88 1998 327 333
91. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists JAMA 271 1994 777 781
92. D.J. Cook, M.A. Crowther, and M. Meade Deep vein thrombosis in medical-surgical ICU patients: prevalence, incidence and risk factors Crit Care 7 2003 S2 S54
93. M.S. Avidan, E.L. Alcock, and F.J. Da Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery Br J Anaesth 92 2004 178 186
94. M.S. Kruskall The perils of platelet transfusions N Engl J Med 337 1997 1914 1915
95. S. Murphy Preservation and clinical use of platelets E. Beutler M.A. Lichtman B.S. Coller Williams' hematology 2001 McGraw-Hill New York 1905 1916
96. J.F. Bishop, K. McGrath, and M.M. Wolf Clinical factors influencing the efficacy of pooled platelet transfusions Blood 71 1988 383 387
97. D.F. O'Shaughnessy, C. Atterbury, and M.P. Bolton Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant Br J Haematol 126 2004 11 28
98. D.M. Surgenor, E.L. Wallace, and W.H. Churchill Red cell transfusions in coronary artery bypass surgery (DRGs 106 and 107) Transfusion 32 1992 458 464
99. Consensus conference Perioperative red blood cell transfusion JAMA 260 1988 2700 2703
100. Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy Anesthesiology 84 1996 732 747
101. A.W. Bracey, R. Radovancevic, and S.A. Riggs Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome Transfusion 39 1999 1070 1077
102. T.E. Warkentin, and M.A. Crowther Reversing anticoagulants both old and new Can J Anaesth 49 2002 S11 S25
103. M.A. Crowther, L.R. Berry, and P.T. Monagle Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin Br J Haematol 116 2002 178 186
104. G.F. Bashein, M.L. Nessly, and A.F. Rice Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery Arch Intern Med 151 1991 89 93
105. C.J. Watson, A.M. Deane, and P.T. Doyle Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin Br J Urol 66 1990 85 87
106. J.C. Merritt, and D.L. Bhatt The efficacy and safety of perioperative antiplatelet therapy J Thromb Thrombolysis 17 2004 21 27
107. P.M. Mannucci, M. Aberg, and I.M. Nilsson Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs Br J Haematol 30 1975 81 93
108. P.M. Mannucci, M.T. Canciani, and L. Rota Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease Br J Haematol 47 1981 283 293
109. J.F. Ansell, V.F. Klassen, and R.F. Lew Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study J Thorac Cardiovasc Surg 104 1992 117 123
110. G.F. Dilthey, W.F. Dietrich, and M.F. Spannagl Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin J Cardiothorac Vasc Anesth 7 1993 425 430
111. I.F. Gratz, J.F. Koehler, and D.F. Olsen The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations J Thorac Cardiovasc Surg 104 1992 1417 1422
112. J.F. Marquez, S. Koehler, and S.R. Strelec Repeated dose administration of desmopressin acetate in uncomplicated cardiac surgery: a prospective, blinded, randomized study J Cardiothorac Vasc Anesth 6 1992 674 676
113. E.W. Salzman, M.J. Weinstein, and R.M. Weintraub Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial N Engl J Med 314 1986 1402 1406
114. D.P. Sheridan, R.T. Card, and J.C. Pinilla Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction Can J Surg 37 1994 33 36
115. B.K. Temeck, L.C. Bachenheimer, and N.M. Katz Desmopressin acetate in cardiac surgery: a double-blind, randomized study South Med J 87 1994 611 615
116. M.F. Cattaneo, A.S. Harris, and U.F. Stromberg The effect of desmopressin on reducing blood loss in cardiac surgery-a meta-analysis of double-blind, placebo-controlled trials Thromb Haemost 74 1995 1064 1070
117. M.F. Levi, M.E. Cromheecke, and E. de Jonge Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints Lancet 354 1999 1940 1947
118. G.J. Despotis, V. Levine, and R. Saleem Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial Lancet 354 1999 106 110
119. P.D. Mongan, and M.P. Hosking The role of desmopressin acetate in patients undergoing coronary artery bypass surgery: a controlled clinical trial with thromboelastographic risk stratification Anesthesiology 77 1992 38 46
120. M.F. Hoylaerts, H.R. Lijnen, and D. Collen Studies on the mechanism of the antifibrinolytic action of tranexamic acid Biochim Biophys Acta 673 1981 75 85
121. S. Thorsen Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids Biochim Biophys Acta 393 1975 55 65
122. M. Verstraete Clinical application of inhibitors of fibrinolysis Drugs 29 1985 236 261
123. P.O. Daily, J.A. Lamphere, and W.P. Dembitsky Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: a randomized, prospective, double-blind study J Thorac Cardiovasc Surg 108 1994 99 106
124. J.M. Karski, S.J. Teasdale, and P. Norman Prevention of bleeding after cardiopulmonary bypass with high-dose tranexamic acid: double-blind, randomized clinical trial J Thorac Cardiovasc Surg 110 1995 835 842
125. D.F. Katsaros, M.F. Petricevic, and N.J. Snow Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients Ann Thorac Surg 61 1996 1131 1135
126. T.J. Vander Salm, S. Kaur, and R.A. Lancey Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid J Thorac Cardiovasc Surg 112 1996 1098 1107
127. Y.F. Kamada, M.F. Yamakage, and T.F. Niiya Celite-activated viscometer Sonoclot can measure the suppressive effect of tranexamic acid on hyperfibrinolysis in cardiac surgery J Anesth 15 2001 17 21
128. Y.F. Kang, J.H. Lewis, and A.F. Navalgund Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation Anesthesiology 66 1987 766 773
129. H.F. Fritz, and G. Wunderer Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs Arzneimittelforschung 33 1983 479 494
130. B.P. Bidstrup, D. Royston, and R.N. Sapsford Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol) J Thorac Cardiovasc Surg 97 1989 364 372
131. W.F. Dietrich, M.F. Spannagl, and M.F. Jochum Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization Anesthesiology 73 1990 1119 1126
132. M.P. Harder, L. Eijsman, and K.J. Roozendaal Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass Ann Thorac Surg 51 1991 936 941
133. B.F. Blauhut, W.F. Harringer, and P.F. Bettelheim Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass J Thorac Cardiovasc Surg 108 1994 1083 1091
134. A.F. Menichetti, L.F. Tritapepe, and G.F. Ruvolo Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid J Cardiovasc Surg (Torino) 37 1996 401 407
135. E. Rocha, F. Hidalgo, and R. Llorens Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery Circulation 90 1994 921 927
136. S.E. Fremes, B.I. Wong, and E. Lee Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding Ann Thorac Surg 58 1994 1580 1588
137. D.F. Henry, A.J. Moxey, and P.A. Carless Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion Cochrane Database Syst Rev 1 2001 CD001886
138. P.M. Mannucci Hemostatic drugs N Engl J Med 339 1998 245 253
139. L.T. Goodnough Experiences with recombinant human factor VIIa in patients with thrombocytopenia Semin Hematol 41 Suppl 1 2004 25 29
140. B.F. Vidarsson, and P.T. Onundarson Recombinant factor VIIa for bleeding in refractory thrombocytopenia Thromb Haemost 83 2000 634 635
141. A.M. Almeida, K. Khair, and I. Hann The use of recombinant factor VIIa in children with inherited platelet function disorders Br J Haematol 121 2003 477 481
142. M.F. Peters, and H. Heijboer Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa Thromb Haemost 80 1998 352
143. H.J. Ng, L.P. Koh, and L.H. Lee Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin Ann Hematol 82 2003 257 258
144. I.F. Veshchev, H.F. Elran, and K. Salame Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma Med Sci Monit 8 2002 CS98 CS100
145. U.F. Martinowitz, G.F. Kenet, and E. Segal Recombinant activated factor VII for adjunctive hemorrhage control in trauma J Trauma 51 2001 431 438 [discussion: 438-9]
146. D.M. Al, T. Shafi, and K.D. Al Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery Blood Coagul Fibrinolysis 11 Suppl 1 2000 S121 S127
147. J.R. Egan, A. Lammi, and D.N. Schell Recombinant activated factor VII in paediatric cardiac surgery Intensive Care Med 30 2004 682 685
148. D.R. McIlroy, and A.J. Silvers Recombinant factor VIIa for life-threatening bleeding in high-risk cardiac surgery despite full-dose aprotinin Anesth Analg 99 2004 27 30
149. K.A. Tanaka, A.A. Waly, and W.A. Cooper Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven) Anesthesiology 98 2003 1513 1515
150. M. Herbertson Recombinant activated factor VII in cardiac surgery Blood Coagul Fibrinolysis 15 Suppl 1 2004 S31 S32
151. N.R. Bijsterveld, R. Vink, and B.E. van Aken Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers Br J Haematol 124 2004 653 658
152. P.W. Friederich, M. Levi, and K.A. Bauer Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects Circulation 103 2001 2555 2559
153. T.F. Lisman, N.R. Bijsterveld, and J.F. Adelmeijer Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux J Thromb Haemost 1 2003 2368 2373
154. J.I. Weitz, J. Hirsh, and M.M. Samama New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 265S 286S
155. G.F. Lefevre, M.F. Duval, and S. Gauron Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin Clin Pharmacol Ther 62 1997 50 59
156. J.I. Weitz, and M. Crowther Direct thrombin inhibitors Thromb Res 106 2002 V275 V284
157. T.E. Warkentin, and A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann Thorac Surg 76 2003 2121 2131
158. G. Huhle, U. Hoffmann, and X. Song Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment Br J Haematol 106 1999 195 201
159. I.F. Fox, A.F. Dawson, and P.F. Loynds Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans Thromb Haemost 69 1993 157 163
160. H. White Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial Lancet 358 2001 1855 1863
161. G.F. Gordon, H.F. Rastegar, and R.F. Schumann Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia J Cardiothorac Vasc Anesth 17 2003 632 635
162. J.C. Vasquez, A. Vichiendilokkul, and S. Mahmood Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery Ann Thorac Surg 74 2002 2177 2179
163. B. Alsoufi, L.K. Boshkov, and A. Kirby Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 7 2004 155 171
164. H.F. Ohno, M.F. Higashidate, and T. Yokosuka Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery Heart Vessels 18 2003 40 42
165. G. Young, K.E. Yonekawa, and P. Nakagawa Recombinant factor VIIa reverses the anticoagulant effects of argatroban, bivalirudin, fondaparinux, enoxaparin, and heparin as assessed ex vivo by thromboelastography Blood 104 2004 517a
166. H.N. Magnani, R.J.R. Beijering, and J.W. ten Cate Orgaaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia R. Pifarre New anticoagulants for the cardiovascular patient 1997 Hanley & Belfus Philadelphia 487 500
167. B.F. Boneu, J.F. Necciari, and R.F. Cariou Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man Thromb Haemost 74 1995 1468 1473
168. J.M. Herbert, J.P. Herault, and A. Bernat Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide Blood 91 1998 4197 4205
169. P.W. Bergum, A. Cruikshank, and S.L. Maki Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2 J Biol Chem 276 2001 10063 10071
170. M.F. Cappello, G.P. Vlasuk, and P.W. Bergum Ancylostoma caninum anticoagulant peptide: a hookworm-derived inhibitor of human coagulation factor Xa Proc Natl Acad Sci U S A 92 1995 6152 6156
171. A.Y. Lee, and G.P. Vlasuk Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor J Intern Med 254 2003 313 321